Priced for one buyer, wanted by many: management describes new sources of demand converging on the same thing it already
The model's full reasoning — Q2 2023 call → NOWe need to determine if the transcript describes a widening demand base for the company's existing offering, with multiple sources of demand converging, and management responding with steps to serve or allocate among them. The company is Nanobiotix, developing NBTXR3, a radioenhancer for solid tumors. The transcript discusses partnerships with Janssen and MD Anderson, and various clinical trials. The question is about demand for the same thing the company already makes or does coming from more than one direction. The company's product is NBTXR3, which is in clinical development. It is not yet commercially available (except maybe in Europe for soft tissue sarcoma? The transcript mentions a positive Phase 3 in soft tissue sarcoma leading to approval in Europe, but that's not the focus). The company is still in clinical trials. The demand here is not from buyers or customers in a commercial sense; it's about clinical development and partnerships. The "demand" could be interpreted as interest from partners, or the expansion of indications. However, the question specifically asks about "demand for the same thing the company already makes or does" - meaning the existing offering. The company's existing offering is NBTXR3, but it's not yet a commercial product for most indications. The transcript discusses multiple clinical trials in different cancers, and partnerships with Janssen and MD Anderson. But is that a widening of demand? The company is still developing the product. The "demand" is not from buyers but from researchers and partners. The question is about a convergence of distinct sources of demand competing for the same output. That doesn't fit here. The company is not selling a product; it's developing a therapy. The transcript talks about clinical progress, not market demand. There is no mention of orders, customers, or commercial sales. The only commercial aspect is the European approval for soft tissue sarcoma, but that's not discussed as a source of demand. The partnership with Janssen is about co-development and commercialization, but that's not demand for an existing product; it's a collaboration to develop further. The question requires that the thing being demanded is already what the company does. The company's product is in clinical trials, not yet a commercial product for most indications. So the answer is likely NO.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| LINC | Lincoln Educational Services Corporation | Q1 2024 | 2024-05-06 | B+ |
| WEC | WEC Energy Group, Inc. | Q1 2024 | 2024-05-01 | A |
| OPAD | Offerpad Solutions Inc. | Q3 2023 | 2023-11-01 | C |
| PFIE | Profire Energy, Inc. | Q1 2023 | 2023-05-13 | B |
| PRPH | ProPhase Labs, Inc. | Q1 2023 | 2023-05-11 | F |
| EVGO | EVgo, Inc. | Q2 2022 | 2022-08-09 | C+ |
| OGI | OrganiGram Holdings Inc. | Q3 2022 | 2022-07-14 | B+ |
| ADSE | ADS-TEC Energy PLC | Q4 2021 | 2022-04-28 | D |
| CNS | Cohen & Steers, Inc. | Q2 2017 | 2017-07-20 | B |
| GOGO | Gogo Inc. | Q1 2016 | 2016-05-06 | C+ |
| WK | Workiva Inc. | Q4 2015 | 2016-03-01 | B |
| HPP | Hudson Pacific Properties, Inc. | Q4 2015 | 2016-02-25 | C |
LINC · Q1 2024 → YESThe question is about whether management describes demand for the same thing the company already makes coming from more than one direction at once, with specific criteria. YES Management describes the core offering—curriculum and training capabilities already in place—as now being applied in a new direction: B2B corporate upskilling contracts (e.g., the CMC agreement) alongside campus-based student programs. They explicitly state they are pursuing additional employer contracts and expanding corporate partnerships, with the new 5-year, $6 million CMC deal representing real, recent revenue that contributed nothing to the reported quarter and is still ramping up through site setup and staffing. This meets all three criteria as a single coherent development.
OPAD · Q3 2023 → YESThe question is about whether management describes demand for the same thing the company already makes coming from more than one direction at once, with specific criteria. YES The transcript shows management describing demand for renovations (already part of their core iBuyer operations) now coming from multiple directions: their own inventory, third-party B2B clients (nearly 50 clients, 127% increase in closed projects), and soon homeowners via Rental Captain.
PFIE · Q1 2023 → YESThe question is about whether management describes demand for the same thing the company already makes coming from more than one direction at once, with the demand base widening recently, and manageme...